These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 21474643

  • 1. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
    Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ, Nebulized Antibiotics Study Group.
    Am J Respir Crit Care Med; 2011 Jul 01; 184(1):106-15. PubMed ID: 21474643
    [Abstract] [Full Text] [Related]

  • 2. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.
    Ferrari F, Lu Q, Girardi C, Petitjean O, Marquette CH, Wallet F, Rouby JJ, Experimental ICU Study Group.
    Intensive Care Med; 2009 Oct 01; 35(10):1792-800. PubMed ID: 19652947
    [Abstract] [Full Text] [Related]

  • 3. Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
    Li Bassi G, Motos A, Fernandez-Barat L, Aguilera Xiol E, Chiurazzi C, Senussi T, Saco MA, Fuster C, Carbonara M, Bobi J, Amaro R, De Rosa F, Comaru T, Yang H, Ranzani OT, Marti JD, Rinaudo M, Comino Trinidad O, Rigol M, Bringué J, Ramirez J, Nicolau DP, Pelosi P, Antonelli M, Blasi F, Artigas A, Montgomery AB, Torres A.
    Crit Care Med; 2019 Jun 01; 47(6):e470-e477. PubMed ID: 30882478
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM, Kang SL, Palmer SM, Rybak MJ.
    Antimicrob Agents Chemother; 1995 Aug 01; 39(8):1797-801. PubMed ID: 7486921
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
    Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard JL, Rouby JJ, Nebulized Antibiotics Study Group.
    Anesthesiology; 2012 Dec 01; 117(6):1335-47. PubMed ID: 23132092
    [Abstract] [Full Text] [Related]

  • 6. Nebulized imipenem to control nosocomial pneumonia caused by Pseudomonas aeruginosa.
    Radhakrishnan M, Jaganath A, Rao GS, Kumari HB.
    J Crit Care; 2008 Mar 01; 23(1):148-50. PubMed ID: 18359432
    [No Abstract] [Full Text] [Related]

  • 7. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.
    Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin MH, Le Naour G, Marquette CH, Rouby JJ.
    Intensive Care Med; 2010 Jul 01; 36(7):1147-55. PubMed ID: 20397007
    [Abstract] [Full Text] [Related]

  • 8. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA, Dube L, Caillon J, Bugnon D, Kergueris MF, Navas D, Le Conte P, Baron D, Potel G.
    J Antimicrob Chemother; 2001 May 01; 47(5):617-22. PubMed ID: 11328773
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
    Kaku N, Morinaga Y, Takeda K, Kosai K, Uno N, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K.
    J Antimicrob Chemother; 2017 Apr 01; 72(4):1123-1128. PubMed ID: 27999047
    [Abstract] [Full Text] [Related]

  • 10. Should Aerosolized Antibiotics Be Used to Treat Ventilator-Associated Pneumonia?
    Zhang C, Berra L, Klompas M.
    Respir Care; 2016 Jun 01; 61(6):737-48. PubMed ID: 27235310
    [Abstract] [Full Text] [Related]

  • 11. Nebulized Versus IV Amikacin as Adjunctive Antibiotic for Hospital and Ventilator-Acquired Pneumonia Postcardiac Surgeries: A Randomized Controlled Trial.
    Hassan NA, Awdallah FF, Abbassi MM, Sabry NA.
    Crit Care Med; 2018 Jan 01; 46(1):45-52. PubMed ID: 28857848
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin.
    Gofman N, To K, Whitman M, Garcia-Morales E.
    Am J Health Syst Pharm; 2018 Jul 01; 75(13):953-957. PubMed ID: 29941534
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
    Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR.
    J Antimicrob Chemother; 2008 Apr 01; 61(4):859-68. PubMed ID: 18305202
    [Abstract] [Full Text] [Related]

  • 16. Intravenous versus nebulized ceftazidime in ventilated piglets with and without experimental bronchopneumonia: comparative effects of helium and nitrogen.
    Tonnellier M, Ferrari F, Goldstein I, Sartorius A, Marquette CH, Rouby JJ.
    Anesthesiology; 2005 May 01; 102(5):995-1000. PubMed ID: 15851887
    [Abstract] [Full Text] [Related]

  • 17. Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia.
    Cousson J, Floch T, Guillard T, Vernet V, Raclot P, Wolak-Thierry A, Jolly D.
    Antimicrob Agents Chemother; 2015 Apr 01; 59(4):1905-9. PubMed ID: 25583727
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.